Merck & Co., Inc. (FRA:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 171.48B |
| Revenue (ttm) | 54.17B |
| Net Income (ttm) | 13.97B |
| Shares Out | n/a |
| EPS (ttm) | 5.52 |
| PE Ratio | 12.28 |
| Forward PE | 8.56 |
| Dividend | 2.91 (4.00%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | n/a |
| Average Volume | 2,398 |
| Open | 68.60 |
| Previous Close | 69.90 |
| Day's Range | 68.20 - 68.70 |
| 52-Week Range | 65.50 - 109.60 |
| Beta | n/a |
| RSI | 48.94 |
| Earnings Date | Jul 29, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo Nordisk.
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns
Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck & Co. Inc. (NYSE: MRK) is the...
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
British pharmaceutical giant GSK Plc (NYSE: GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 gu...
Merck & Co. CEO Robert Davis goes one-on-one with Jim Cramer
Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer to talk quarterly results, what sectors it is seeing strength in, its recent acquisition of Verona Pharma and more.
Why Merck Stock Slipped Today
A change in full-year guidance by management wasn't particularly welcome.
Merck Stock Is Almost A Classical Benjamin Graham Investment
Is Merck & Co Gaining or Losing Market Support?
Merck & Co's (NYSE: MRK) short percent of float has fallen 17.95% since its last report. The company recently reported that it has 28.77 million shares sold short , which is 1.28% of all regular shar...
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
'Halftime' Committee Stocks on the Move: UnitedHealth, Merck, Royal Caribbean and Spotify
The Investment Committee debate some of their stocks on the move lower.
'Halftime' Committee Stocks on the Move: UnitedHealth, Merck, Royal Caribbean and Spotify
The Investment Committee debate some of their stocks on the move lower.
Paul MacDonald's Past Picks: Merck & Co, AbbVie & UnitedHealth Group
Paul MacDonald, Chief Investment Officer & Portfolio Manager at Harvest Portfolios Group, discusses his past stock picks and how they're doing in the market today.
Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges
Merck & Co. Inc. (NYSE: MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst co...
MRK Earnings: Merck & Co Q2 adj. profit drops on lower sales
Merck & Co. Inc. (NYSE: MRK) on Tuesday reported lower sales and adjusted earnings for the second quarter of 2025. The company also announced the acquisition of Verona Pharma plc. […] The post MRK Ear...
US market today: Stocks edge higher as Fed meet, China tariff talks weigh; JetBlue, SoFi jump while Merck, UnitedHealth drag
Wall Street saw modest gains, with the S&P 500 and Nasdaq reaching new highs, as investors awaited the Federal Reserve's rate decision and developments in US-China trade talks. JetBlue and SoFi Techno...
Merck will lay off employees and shed some real estate to cut $3 billion in costs
Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.
Merck & Co., Inc. 2025 Q2 - Results - Earnings Call Presentation
Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop
Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring initiative.
Merck Posts Q2 EPS Beat Revenue Slips
Merck plans $3 billion cost cuts by end of 2027 - narrows full-year outlook
CNBC's Joe Kernen reports on the company's quarterly earnings results.